Long-term entecavir efficacy retention in the treatment of chronic hepatitis B with an outcome to hepatic cirrhosis caused by its resistant virus strain


Cite item

Full Text

Abstract

The paper gives concise data on the efficacy of entecavir in the treatment of chronic hepatitis B caused by its resistant virus strain and describes a relevant clinical case.

About the authors

O O Znoĭko

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России

Email: olgaznoyko@yandex.ru

K R Dudina

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России

N Kh Safiullina

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России

I V Karandashova

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора

V P Chulanov

ФБУН Центральный НИИ эпидемиологии Роспотребнадзора

References

  1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection J Hepatol 2012; 57 (1): 167-185.
  2. Tenney D.J., Rose R.E., Baldick C.J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49 (5): 1503-1514.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies